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012.04.00Abstract Introduction: IL-27 exerts profound anti-inﬂammatory effects in several experimental
autoimmune models, suggesting that it may be therapeutically relevant in SLE.
Aim of the work: To evaluate IL-27 level in SLE patients and its association to clinical manifes-
tations, disease activity parameters and management strategy.
Patients and methods: We studied 80 SLE patients and 50 controls in a cross sectional study.
Demographic, clinical and serological data were evaluated. Systemic lupus erythematosus disease
activity index (SLEDAI) and Systemic Lupus International Collaboration Clinics/ACR damage
index (SLICC) were assessed. Serum IL-27 was measured by ELISA.
Results: There was statistically signiﬁcant difference in IL-27 level in SLE patients and healthy
controls (9.7 ± 21.9 pg/ml vs 20.2 ± 47.3 pg/ml in SLE vs controls, respectively) (p= 0.04), also it
was found that IL-27 level was statistically signiﬁcantly lower in SLE patients with lupus nephritis
(p= 0.02) and cerebritis (p= 0.03). Interleukin 27 level had a statistically signiﬁcant negative cor-
relation with the cumulative dose of hydroxychloroquine and azathioprine (r= 0.3, p= 0.03 and
r= 0.3 and p= 0.04, respectively).
Conclusion: IL-27 has anti-inﬂammatory effect in SLE patients especially those without nephritis
or cerebritis and can be therapeutically relevant in SLE. To conﬁrm our results we propose larger
scale, multicentre studies with longer evaluation periods.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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21. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease characterized by the production of many autoantibod-
ies, complement activation, and immune-complex deposition,
causing tissue and organ injury. The pathogenetic mechanisms
of SLE are still unclear. Many mechanisms could contribute to
this disease. Activated autoreactive T helper (Th) cells have
been shown to be implicated in the pathogenesis of SLE, whichuction and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.
100 W. Gaber et al.help B cells to differentiate and produce pathogenic autoanti-
bodies [1].
1.1. IL-27 is one of IL-12 cytokine family affecting T cells
Interleukin 27 was identiﬁed to be related to the IL-12 cytokine
family. These family members play important roles in the reg-
ulation of Th cell differentiation. It has been found that IL-27
is also involved in the regulation of Th17 responses, suppress-
ing Th17 differentiation and IL-17 production [2]. In this con-
text, IL-27 has an immunosuppressive feature as anti-
inﬂammatory effects of IL-27 have also been demonstrated
in various experimental settings. Thus, IL-27 seems to have
two distinct functions in immune responses: one as an initiator
of Th1-type immune responses and the other as an attenuator
of immune/inﬂammatory responses [3].
IL-12, a heterodimeric cytokine composed of two subunits,
p35 and p40, is critical in Th1 differentiation [4]. Also IL-23
and IL-27 were identiﬁed as heterodimeric cytokines function-
ally and structurally related to IL-12 [5]. In addition, IL-35 was
identiﬁed as a new IL-12 family member which is composed of
Epstein-Barr-induced molecule 3 (EBI-3) and p35 [6].
IL-23 is composed of the p40 subunit of IL-12 and p19, but
IL-27 is composed of EBI-3, a p40-related molecule, a p28 and
a p35-related molecule [7].
IL-12R is composed of two subunits: b1 and b2. Down-
stream of IL-12R, STAT4 is activated for direct induction of
the IFN-c gene. IL-23R uses unique IL-23R subunits and
shares IL-12R b 1 subunits. IL-27R is made with WSX-1 (also
called the IL-27Ra chain or T cell cytokine receptor) and
gp130, the signal transducing subunit of the IL-6R complex.
Downstream of IL-27R, STAT1 and STAT3 are activated by
ligand binding, IL-35R has not been identiﬁed yet [8].
IL-27 enhances cytotoxic activity against tumors of CD8+
T cells. IL-27R signaling is critical in STAT1 and T-bet-in-
duced IFN-c production by CD8+ T cells [9]. Hisada et al.
[10] reported that C26 cells engineered to produce IL-27 con-
ferred protective immunity in a CD8+ T cells and IFN-c-
dependent manner when inoculated in immuno-competent
mice. The effect was also dependent on T-bet activation. IL-
27 produced by tumor cells also enhanced IFN-c production
by NK cells. STAT1- and T-bet-dependent augmentation of
IL-12Rb2, granzyme B, and perforin expression in CD8+ T
cells by tumor derived IL-27 was observed in vitro [11].
1.2. Effects of IL-27 on other types of cells
IL-27 also has an impact on B cell differentiation and Ig pro-
duction. IL-27 induced proliferation of activated naive B cells
but not memory B cells, indicating that IL-27 exerts differen-
tial effects on B cells depending on activation/differentiation
status of the cells [12]. IL-27 stimulation of mouse B cells in-
duced STAT1 activation and T-bet expression followed by
class-switching of B cells to IgG2a (Th1-dependent Ig subtype)
producing cells In contrast, IL-27 inhibited IgG1 (Th2-depen-
dent Ig subtype) class-switching. Interestingly, IL-27 up regu-
lates IL-4 induced IgE production by naive B cells without
affecting Ce promoter activity. STAT1 and T-bet-dependent
activation of B cells and Th1-related Ig production are also
reminiscent of the effects of IL-27 on naive CD4+ T cells. [13].
IL-27 augments NK cell activity although the enhancement
of IFN-c production in NK cells by the inoculation of IL-27-producing tumor cells was reported [14], Oniki et al. [15] re-
ported IFN-c-independent enhancement of NK cell-mediated
anti-tumor immunity by IL-27.
Effects of IL-27 on macrophage/monocyte are complicated
too. It was reported that IL-27-mediated augmentation of
MHC class I/II expression as well as transporter associated
with antigen processing 1 and b2-microglobin expression in a
THP-1 human monocyte cell line [16]. Expression of costimu-
latory molecules CD80 and CD86 and an adhesion molecule
CD54 was also augmented by IL-27. Thus, IL-27 may enhance
immune responses by the induction of genes involved in anti-
gen presenting activity of THP-1 cells. IL-27-stimulated mono-
cytes showed enhanced TLR responsiveness and produced
more IL-6 and TNF-a as compared with cells without IL-27
stimulation [3].
Caroline Diveu et al. [17] reported that, IL 27R-deﬁcient
mice infected with Toxoplasma gondii, an encephalitis model,
developed severe neuroinﬂammation associated with exagger-
ated T cell responses and overproduction of IFN-c and
TNF-a during the acute phase of the disease; mortality was
high due to uncontrolled immune pathology [18]. Additionally,
an increased frequency of Th17 cells was found in the brains of
Toxoplasma-infected IL-27R-deﬁcient mice during the chronic
phase of infection [19]. The IL-27R-deﬁcient mice are also hy-
per susceptible to experimental autoimmune encephalomyelitis
(EAE) and more Th17 cells were generated in these mice as
well [20]. These two reports stress that IL-27 negatively regu-
lates the development of Th17 cells in vivo. It is important
to point out that these studies are based on the assumption
that IL-27R is the only receptor for IL-27. Similar studies in
IL-27p28 or IL-27 EBI3-deﬁcient mice have not yet been per-
formed to conﬁrm this assumption [17].
Since it has been demonstrated that IL-27 has two conﬂict-
ing properties: pro-inﬂammatory and anti-inﬂammatory,
therefore in the present study we investigated the serum IL-
27 level in SLE patients and its relation to various disease
parameters and treatment strategy.2. Patients and methods
2.1. Patients
Eighty SLE patients were recruited consecutively, 97.5% of
them are females and 2.5% are males fulﬁlling the updated
American College of Rheumatology (ACR) revised criteria
for the classiﬁcation of SLE [21] were consecutively recruited
from Rheumatology Department, Cairo University Hospitals.
Full history taking, thorough clinical examination and labora-
tory investigations were done. Assessment of disease activity
was done using the Systemic lupus erythematosus disease
activity index (SLEDAI) [22], disease damage using the Sys-
temic Lupus International Collaboration Clinics/ACR damage
index (SLICC/DI) [23]. Secondary APS was diagnosed accord-
ing to the Sapporo criteria [24]. Informed consents were taken
from the patients and the study was approved by the local eth-
ics committee.
2.2. Renal biopsy
The kidney biopsy was performed in all patients who had
either proteinuria (urinary protein concentrationP 500 mg/
Table 1 Descriptive data of the studied SLE patients and its
correlation to IL 27 level.
Characteristics Value n (%), mean ± SD
Duration (years) 5.6 ± 4.6
Age (mean ± SD) 29.3 ± 9.8
Nephritis (No. (%)) 64/80 (80%)
s Class II
s Class III
s Class IV
s Class V
s Class II–V
c Active nephritis
c Chronic nephritis
12/64 (18.8%)
15/64 (23.4%)
30/64 (46.9%)
4/64 (6.3%)
3/64 (4.7%)
40/64 (62.5%)
24/64 (37.5%)
Neuropsychiatric manifestations 28/80 (35%)
Psychosis (No. (%)) 18/80 (22.5%)
Seizure (No. (%)) 7/80 (22.5%)
Lupus headache (No. (%)) 3/80 (3.8%)
Mucocutaneous manifestations (No. (%)) 69/80 (86.3%)
Serositis (No. (%)) 64/80 (80%)
Arthritis (No. (%)) 37/80 (46.3%)
BMI (kg/m2) (mean ± SD) 25.9 ± 6.5
SLEDAI score (mean ± SD) 17.3 ± 8.5
SLICC (mean ± SD) 0.6 ± 0.9
Hypertension (No. (%)) 36/80 (45%)
Diabetes mellitus (No. (%)) 6/80 (7.5%)
Laboratory data
IL-27(pg/ml) (mean ± SD) 9.7 ± 21.9
HGB (g/dl) (mean ± SD) 10.7 ± 1.3
TLC (103/mm3) (mean ± SD) 4.5 ± 1.3
Platelets (103/mm3) (mean ± SD) 150.7 ± 30.5
GFR(ml/min) (mean ± SD) 70.4 ± 21.3
Cholesterol (mg/dl) (mean ± SD) 168.7 ± 60.4
Triglycerides (mg/dl) (mean ± SD) 155.2 ± 73.1
HDL (mg/dl) (mean ± SD) 49.3 ± 15.6
LDL (mg/dl) (mean ± SD) 175.2 ± 39.1
ALT (U/L) (mean ± SD) 20.4 ± 7.2
AST (U/L) (mean ± SD) 18.9 ± 9.8
FBS (mg/dl) (mean ± SD) 93.1 ± 17.9
ACL positive (No. (%)) 18/80 (22.5%)
LAC positive (No. (%)) 14/80 (17.5%)
Creatinine (mg/dl) (mean ± SD) 0.8 ± 0.4
C3 (mg/dl) (mean ± SD) 80 ± 37
C4 (mg/dl) (mean ± SD) 17.1 ± 7.2
CRP (mg/dl) (mean ± SD) 3.7 ± 11.8
BMI: body mass index, SLEDAI: Systemic lupus erythematosus
disease activity index, SLICC: Systemic Lupus International Col-
laboration Clinics/ACR damage index, IL-27: Interleukin 27,
HGB: hemoglobin, TLC: total leukocyte count, GFR: glomerular
ﬁltration rate, HDL: high density lipoprotein, LDL: low density
lipoprotein, ALT: alanine transferase, AST: aspartame transferase,
FBS: fasting blood sugar, ACL: anticardiolipin antibody, LAC:
lupus anticoagulant,C3:complement 3, C4: complement 4, CRP: C-
reactive protein.
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nine level. The biopsy specimens had been studied, using light
and immunoﬂuorescence microscopy, by renal pathologists
who had no knowledge of the clinical and laboratory features
of the patients. The World Health Organization (WHO) clas-
siﬁcation of lupus glomerulonephritis [25] and the WHO activ-
ity and chronicity index scores [26] were evaluated.
2.3. Laboratory investigations
Blood was drawn at the time of the study for analyses which
included the following: antiphospholipid antibodies (aPL) (po-
sitive if IgG or IgM ACL was >40 IU/ml or if the lupus anti-
coagulants (‘‘LAC’’) was present). Antinuclear antibody
testing (ANA), anti-DNA using indirect immunoﬂuorescence,
C-reactive protein (CRP), serum complement (C3 and C4) lev-
els by nephelometry and glomerular ﬁltration rate were done
to all patients. A complete blood picture, lipid proﬁle, serum
creatinine, fasting blood sugar and liver functions were tested
for all enrolled cases.
Human IL-27 in serum was measured by sandwich enzyme-
linked immunosorbent assay; reagents were supplied by Ray-
Bio [27] and according to the manufacturer’s recommendation.
Brieﬂy, 96-well plates coated with biotinylated IL-27 were
incubated with 100-KL sera for 120 min at 37-C. Then, the
plates were washed 6 times with the wash solutions of the kits.
Biotinylated abs of 100 KL was pipetted into each of the
microplate wells and incubated for 60 min at room tempera-
ture. After 6 washes, 100 KL of enzyme conjugate was added
and incubated for 30 min at 37-C and then washed as before.
A 100-KL tetramethyl benzidine solution was added and incu-
bated for 15 min in the dark. Color release was stopped with
the addition of 100 KL of stop solution. The microplate wells
were read at 450-nm reference ﬁlter within 30 min, and the
optical density value of each well was recorded. Then, the con-
centrations were calculated according to the optical density
values, and the results were expressed as picograms per millili-
ter (intraassay: coefﬁcient of variation, G10%; interassay:
coefﬁcient of variation, G15%) [28].
Statistics: Statistical analysis, Statistical Package for Social
Science program, version 15, was used for analysis of data.
Data were presented as number (percent) and mean ± SD.
Mann–Whitney test was used for the analysis of two quantita-
tive data. Spearman correlation was used for detection of the
relation between two variables. P value was considered signif-
icant if <0.05 [29] .
3. Results
3.1. Data of all studied SLE patients
Eighty SLE patients (78 females and 2 males) (39:1 female/
male, respectively) were examined during this study with a
mean age of 29.3 ± 9.8 years and a mean disease duration of
5.6 ± 4.7 years (as shown in Table 1) as well as 50 controls
(49 females and one male) matched for age and sex, as their
mean age was 27.6 ± 10.4 years. All patients were taking ste-
roids (dose ranged from 15 to 45 mg/day), all patients were
on hydroxychloroquine (dose ranged from 200 to 400 mg/
day), 74 patients on azathioprine (dose ranged from 100 to
150 mg/day) and 44 patients were receiving monthly cyclo-phosphamide pulse therapy depending on extent of renal lesion
(dose ranged from 600 to 1000 mg (as shown in Table 2).
3.2. IL-27 in SLE patients and control group
Interleukin-27 level in SLE patients was statistically signiﬁ-
cantly lower than in the control group with mean ± SD of
Mean ± SD  of IL 27 level for patients  and
control group
Figure 1 IL-27 in SLE patients and control group.
Table 2 Medications used in the studied group.
Current medications Mean ± S.D.
Steroid cumulative dose (g) (mean ± SD) 1.1 ± 0.6
HQN cumulative dose (g) (mean ± SD) 17.1 ± 11.4
Azathioprine cumulative dose (g) (mean ± SD) 3.6 ± 3
CYC cumulative dose (g) (mean ± SD) 3.8 ± 3.8
HQN: hydroxychloroqiune, CyC: cyclophosphamide.
Table 3 IL-27 and its correlation to clinical and laboratory
parameters.
Characteristics Value n (%), mean ± SD P value
Duration (years) 5.6 ± 4.6 0.2
Age mean 29.3 ± 9.8 0.9
Nephritis 64/80 (80%) 0.03*
Psychosis 18/80 (22.5%) 0.04*
Seizure 7/80 (22.5%) 0.06
Lupus headache 3/80 (3.8%) 0.07
Mucocutaneous manifestaions 69/80 (86.3%) 0.7
Serositis 64/80 (80%) 0.8
Arthritis 37/80 (46.3%) 0.6
BMI (kg/m2) 25.9 ± 6.5 0.4
Hypertension 36/80 (45%) 0.09
Diabetes mellitus 6/80 (7.5%) 0.9
Laboratory data
IL-27(pg/ml) 9.7 ± 21.9
HGB (g/dl) 10.7 ± 1.3 0.3
TLC (103/mm3) 4.5 ± 1.3 0.4
Platelets (103/mm3) 150.7 ± 30.5 0.2
GFR (ml/min) 70.4 ± 21.3 0.06
Cholesterol (mg/dl) 168.7 ± 60.4 0.4
Triglycerides (mg/dl) 155.2 ± 73.1 0.6
HDL (mg/dl) 49.3 ± 15.6 0.5
LDL (mg/dl) 175.2 ± 39.1 0.9
ALT (U/L) 20.4 ± 7.2 0.7
AST (U/L) 18.9 ± 9.8 0.6
FBS (mg/dl) 93.1 ± 17.9 0.1
ACL positive 18/80 (22.5%) 0.5
LAC positive 14/80 (17.5%) 0.4
Creatinine (mg/dl) 0.8 ± 0.4 0.07
C3 (mg/dl) 80 ± 37 0.3
C4 (mg/dl) 17.1 ± 7.2 0.6
CRP (mg/dl) 3.7 ± 11.8 0.08
BMI: body mass index, IL-27: Interleukin 27, HGB: hemoglobin,
TLC: total leukocyte count, GFR: glomerular ﬁltration rate, HDL:
high density lipoprotein, LDL: low density lipoprotein, ALT: ala-
nine transferase, AST: aspartame transferase, FBS: fasting blood
sugar, ACL: anticardiolipin antibody, LAC: lupus anticoagulant,
C3: complement 3, C4: complement 4, CRP: C-reactive protein.
* Statistically signiﬁcant value (p< 0.05).
Table 4 IL-27 in SLE patients with nephritis and cerebritis.
SLE patients IL-27 level (mean ± S.D) P value
Nephritis 0.02*
Yes 1 ± 1.1
No 11.7 ± 27.5
Cerebritis 0.03*
Yes 2 ± 0.9
No 11.9 ± 24.5
* Statistically signiﬁcant value (p < 0.05).
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0.04) as (shown in Fig. 1).
3.3. IL-27 in SLE patients and its relation to all clinical and
laboratory parameters
On correlating IL-27 level to all clinical and laboratory param-
eters, a signiﬁcant negative correlation was found with psycho-
sis and nephritis (p= 0.04 and p= 0.03, respectively,
r= 0.2, and r= 0.3, respectively). But there was no signif-
icant correlation with other clinical manifestations or labora-
tory parameters (as shown in Table 3).
3.4. IL-27 in SLE with renal and neuropsychiatric
manifestations
On comparing SLE patients with and without nephritis it was
found that, IL-27 level was signiﬁcantly lower in patients with
nephritis (p= 0.02). Also it was found that, the level of IL-27
was signiﬁcantly lower in patients with cerebritis (p= 0.03) (as
shown in Table 4).
3.5. Relation of IL-27 to disease activity measures and damage
index
On correlating the level of IL-27 and disease activity score, it
was found that IL-27 had no statistically signiﬁcant correlation
with SLEDAI score (r= 0.3 and p= 0.06), or damage index
SLICC score (r= 0.1 and p= 0.5) (as shown in Table 5).3.6. Il-27 and its relation to the received medications
Interleukin 27 level had a statistically signiﬁcant negative cor-
relation with the cumulative dose of hydroxychloroquine and
azathioprine (r= 0.3, p= 0.03 and r= 0.3 and
p= 0.04, respectively) (as shown in Table 5) and (Graphs 1
and 2).
HQN cumulative dose (gm)
50.0040.0030.0020.0010.000.00
100.00
80.00
60.00
40.00
20.00
0.00
Patients IL27 level (pg/ml) 
Linear
Observed
Graph 1 Il-27 and its relation to hydroxychloroquine cumulative
dose.
Table 5 IL-27 and relation to the disease activity and damage
indices and medications used in the studied group.
Disease activity and damage index Mean ± S.D P value
SLEDAI score 17.3 ± 8.5 0.06
SLICC 0.6 ± 0.9 0.5
Current medications
Steroid cumulative dose (g) 1.1 ± 0.6 0.1
HQN cumulative dose (g) 17.1 ± 11.4 0.03*
Azathioprine cumulative dose (g) 3.6 ± 3 0.04*
CYC cumulative dose (g) 3.8 ± 3.8 0.5
SLEDAI: Systemic lupus erythematosus disease activity index,
SLICC: Systemic Lupus International Collaboration Clinics/ACR
damage index, HQN: hydroxychloroquine, CyC:
cyclophosphamide.
* Statistically signiﬁcant value (p< 0.05).
Azathioprine cumulative dose (gm)
14.0012.0010.008.006.004.002.000.00
100.00
80.00
60.00
40.00
20.00
0.00
Linear
Observed
Patients IL27 level (pg/ml)
Graph 2 Il-27 and its relation to azathioprine cumulative dose.
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In the present study we found that interleukin-27 level in SLE
patients was statistically signiﬁcantly lower than that in the
control group (p= 0.04), this coincides with the results of Li
et al. [28], who examined Fifty-six patients with SLE and 30
healthy volunteers were recruited. Serum IL-27 levels were de-
tected by enzyme-linked immunosorbent assay. The clinical
and laboratory parameters were collected from medical re-
cords or by questionnaire. The serum IL-27 level in SLE pa-
tients was signiﬁcantly lower than that in healthy controls
(P< 0.001).
This can be explained as interleukin-27 is being consumed
in several experimental autoimmune models. As its presence
had suppressive effects on T(h)17 cells, which are implicated
in the pathogenesis of SLE. Moreover, administration of IL-
27 or augmentation of IL-27 signaling suppresses some auto-immune diseases, including autoimmune diabetes and murine
lupus, suggesting that IL-27 may be therapeutically relevant
in SLE [30].
Li et al. [28] reported that, compared to SLE patients with-
out nephritis, patients with nephritis had a signiﬁcantly de-
creased serum IL-27 level (P< 0.05) and this coincides with
the results in the present study, as we found that, IL-27 level
was signiﬁcantly lower in patients with nephritis (p= 0.02)
in comparison to patients without nephritis.
This can be explained partially with the results of Yu and
Gaffen [31] who considered that IL-17 can promote the
recruitment of inﬂammatory cells to target organs such as kid-
ney. Where as Th17 differentiation and IL-17 production
could be suppressed by IL-27.
In the current study, there was no statistically signiﬁcant
correlation with SLEDAI score (p= 0.06), or damage index
SLICC score (p= 0.5). This coincides with the results of Li
et al. [28] who found no signiﬁcant difference between less ac-
tive and more active SLE patients (P> 0.05).
On reviewing all the available literature, there were no
available data on the association of IL-27 and cerebritis except
in murine models, in the current study, we found that the level
of IL-27 was signiﬁcantly lower in patients with cerebritis and
this can be explained by the results of Stumhofer et al. [19],
who reported that, many studies had focused on the events
that inﬂuence the development of interleukin 17 (IL-17)-pro-
ducing T helper cells (TH-17 cells) associated with autoimmu-
nity, such as experimental autoimmune encephalitis (EAE),
but relatively little is known about the cytokines that antago-
nize TH-17 cell effector responses. So Stumhofer et al. [19]
showed that IL-27 receptor-deﬁcient mice chronically infected
with Toxoplasma gondii developed severe neuro-inﬂammation
that was CD4+ T cell dependent and was associated with a
prominent IL-17 response. In vitro, treatment of naive primary
T cells with IL-27 suppressed the development TH-17 cells in-
duced by IL-6 and transforming growth factor-b, which was
dependent on the intracellular signaling molecule STAT1 but
was independent of inhibition of IL-6 signaling mediated by
104 W. Gaber et al.the suppressor protein SOCS3. Thus IL-27, a potent inhibitor
of TH-17 cell development, may be a useful target for treating
inﬂammatory diseases mediated by these cells.
In the present study, it was found that IL-27 had statisti-
cally signiﬁcant negative correlation with the cumulative dose
of hydroxychloroqiune and azathioprine (p= 0.03 and
p= 0.04, respectively), and this could be explained as in active
SLE, patients need higher doses of medications for longer
duration than quiescent patients and this also proves that or-
gan inﬂammation in SLE patients as nephritis and cerebritis
show low level of IL27 which may be consumed in inﬂamma-
tion. But there was no available studies commenting on the
relation of IL27 to the medications received as they studied pa-
tients before taking any medications, but studies recommended
the use of IL-27 antagonists in conjunction with other stan-
dard therapies for lupus, such as immunosuppressive drugs
(e.g., methotrexate, azathioprine, cyclophosphamide, chloram-
bucil, mycophenolate mofetil, cyclosporine, hydroxychloroqi-
une and the like) [32].
Conclusion: Interleukin-27 exerts profound anti-inﬂamma-
tory effects in SLE patients proved by the lower serum level
of IL-27 in SLE patients with nephritis and cerebritis than
those without. This suggests that IL-27 may be therapeutically
relevant in SLE. Also it was found that IL27 had a
negative correlation with the cumulative dose of HQN and
azathioprine.Conﬂict of Interest
No conﬂict of interest.
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